Withholding Recognized Effective Adjuvant Anti-Neoplastic Chemotherapy in a Setting with Known Highly Active Treatment for Recurrent Disease: A Case Report
A young woman presenting with an ovarian immature teratoma (stage IA, grade 2) demonstrates the dilemma associated with the decision to withhold adjuvant chemotherapy of documented clinical utility in a setting where highly effective treatment is available should the cancer ultimately recur.
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Karger Publishers
2010-07-01
|
| Series: | Case Reports in Oncology |
| Subjects: | |
| Online Access: | http://www.karger.com/Article/FullText/318532 |
| _version_ | 1831562739802177536 |
|---|---|
| author | Maurie Markman |
| author_facet | Maurie Markman |
| author_sort | Maurie Markman |
| collection | DOAJ |
| description | A young woman presenting with an ovarian immature teratoma (stage IA, grade 2) demonstrates the dilemma associated with the decision to withhold adjuvant chemotherapy of documented clinical utility in a setting where highly effective treatment is available should the cancer ultimately recur. |
| first_indexed | 2024-12-17T10:43:23Z |
| format | Article |
| id | doaj.art-c502dbf3e0aa40a79bdaec3fbb7c5fa0 |
| institution | Directory Open Access Journal |
| issn | 1662-6575 |
| language | English |
| last_indexed | 2024-12-17T10:43:23Z |
| publishDate | 2010-07-01 |
| publisher | Karger Publishers |
| record_format | Article |
| series | Case Reports in Oncology |
| spelling | doaj.art-c502dbf3e0aa40a79bdaec3fbb7c5fa02022-12-21T21:52:12ZengKarger PublishersCase Reports in Oncology1662-65752010-07-013223123310.1159/000318532318532Withholding Recognized Effective Adjuvant Anti-Neoplastic Chemotherapy in a Setting with Known Highly Active Treatment for Recurrent Disease: A Case ReportMaurie MarkmanA young woman presenting with an ovarian immature teratoma (stage IA, grade 2) demonstrates the dilemma associated with the decision to withhold adjuvant chemotherapy of documented clinical utility in a setting where highly effective treatment is available should the cancer ultimately recur.http://www.karger.com/Article/FullText/318532Female germ cell tumorAdjuvant chemotherapyToxicity of chemotherapyCisplatin |
| spellingShingle | Maurie Markman Withholding Recognized Effective Adjuvant Anti-Neoplastic Chemotherapy in a Setting with Known Highly Active Treatment for Recurrent Disease: A Case Report Case Reports in Oncology Female germ cell tumor Adjuvant chemotherapy Toxicity of chemotherapy Cisplatin |
| title | Withholding Recognized Effective Adjuvant Anti-Neoplastic Chemotherapy in a Setting with Known Highly Active Treatment for Recurrent Disease: A Case Report |
| title_full | Withholding Recognized Effective Adjuvant Anti-Neoplastic Chemotherapy in a Setting with Known Highly Active Treatment for Recurrent Disease: A Case Report |
| title_fullStr | Withholding Recognized Effective Adjuvant Anti-Neoplastic Chemotherapy in a Setting with Known Highly Active Treatment for Recurrent Disease: A Case Report |
| title_full_unstemmed | Withholding Recognized Effective Adjuvant Anti-Neoplastic Chemotherapy in a Setting with Known Highly Active Treatment for Recurrent Disease: A Case Report |
| title_short | Withholding Recognized Effective Adjuvant Anti-Neoplastic Chemotherapy in a Setting with Known Highly Active Treatment for Recurrent Disease: A Case Report |
| title_sort | withholding recognized effective adjuvant anti neoplastic chemotherapy in a setting with known highly active treatment for recurrent disease a case report |
| topic | Female germ cell tumor Adjuvant chemotherapy Toxicity of chemotherapy Cisplatin |
| url | http://www.karger.com/Article/FullText/318532 |
| work_keys_str_mv | AT mauriemarkman withholdingrecognizedeffectiveadjuvantantineoplasticchemotherapyinasettingwithknownhighlyactivetreatmentforrecurrentdiseaseacasereport |